Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:37:26.238Z.
Calculation as of: 2026-10-06T13:37:26.238Z.
Quote observation: 2026-10-06T13:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a3e1feeb410069f07e4350e21f058018b4d4b1a35d97054c3a706da9d6a2f8d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$85.60M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.52M
EV/FCF Ratio
21.85x
TTM Avg
56.27x
3Y Avg
59.65x
5Y Avg
59.65x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $84.55M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.97M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.44M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $83.92M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $81.10M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.11M | 5.89x | 5.69x | 5.19x | 9.05x |
| ImmuCell Corporation (ICCC)vs › | $88.52M | 21.85x | 56.27x | 59.65x | 59.65x |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $80.15M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $88.84M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
